---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-057186"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:35:20.972448+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Q1 2026 Net Loss Narrowed to $4.6M, FDA Meeting Set for May 20

## Summary
- Net loss for Q1 2026 was $4.6M ($0.05/share), down from $8.5M ($0.14/share) in Q1 2025.
- Cash, cash equivalents, and restricted cash were $31.2M as of March 31, 2026; NIA grant funds $25.6M.
- FDA Division of Psychiatry meeting scheduled for May 20, 2026 to discuss registrational plans for zervimesine in DLB psychosis.
- Topline results from Phase 2 START study (COG0203) in early Alzheimer's expected in 2027.
- Presented two posters at AD/PD 2026 conference on zervimesine's effect and composite endpoint for DLB.

## SEC filing metadata
- accession: 0001104659-26-057186
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465926057186/0001104659-26-057186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465926057186/tm2613845d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-057186
- JSON: https://secwatch.observer/filing/0001104659-26-057186.json
- Plain text: https://secwatch.observer/filing/0001104659-26-057186.txt

## Source-grounded claims
- claim_id: 6cee8f15de662fca73dc8c0dc4892c31abf33dd9
  claim: COGNITION THERAPEUTICS INC reported the first quarter ended March 31, 2026 results: net income $4.6 million, EPS $(0.05) per basic and diluted share.
  evidence_excerpt: expenses was driven primarily by lower stock compensation, compensation and professional fees. Cognition Therapeutics, Inc. www.cogrx.com The Company reported a net loss of $4.6 million, or $(0.05) per basic and diluted share for the first quarter ended March 31, 2026, compared to a net loss of $8.5 million, or $(0.14) per basic and diluted share for the same
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465926057186/0001104659-26-057186-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.